Intellia Therapeutics Inc (FRA:38I)
€ 13.565 -0.175 (-1.27%) Market Cap: 1.44 Bil Enterprise Value: 903.64 Mil PE Ratio: 0 PB Ratio: 1.53 GF Score: 57/100

Intellia Therapeutics Inc at Barclays Global Healthcare Conference (Virtual) Transcript

Mar 10, 2021 / 02:45PM GMT
Release Date Price: €49 (+7.67%)
Huidong Wang
Barclays Bank PLC, Research Division - Research Analyst

Good morning, everyone. My name is Gena Wang. I'm SMid-cap biotech analyst at Barclays. Welcome to our second Virtual Global Healthcare conference. First, I wish everyone is safe and healthy. And I would like to thank all the participants, investors, companies and especially our event team and corporate access team who made this virtual health care conference possible.

With that, I would like to introduce our next presenting company, Intellia. With us, we have John Leonard, Chief Executive Officer; Laura Sepp-Lorenzino, Chief Scientific Officer; and Glenn Goddard, Chief Financial Officer.

So with that, I will hand over to John for the introduction slides.

John M. Leonard
Intellia Therapeutics, Inc. - President, CEO & Director

Thank you, Gena. So it's great to be here. Give us 1 second. We have a couple of slides that I think it will be helpful for the audience to get a sense while I just talk a little bit about Intellia. So maybe we can go to the next slide and show

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot